Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab in patients with Cervical Adenocarcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with paclitaxel (175 mg/m^2), carboplatin (AUC-5), and bevacizumab for reimbursement as a treatment option for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.